Zentalis and Pfizer plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells
Adam Schayowitz, Ph.D., MBA, Vice President & Medicine Team Group Lead for Breast Cancer, Colorectal Cancer and Melanoma, Pfizer, to join Zentalis’ Scientific Advisory Board
Cash runway extended into Q1 2024, with Pfizer’s equity investment and budget reallocation
https://finance.yahoo.com/news/zentalis-pharmaceuticals-announces-25-million-110000615.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.